StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
FDA Giving Biogen (BIIB) Option for Aducanumab Approval on Efficacy from ENGAGE Trial, Shares Worth $443 on Approval - Truist
November 4, 2020 10:54 AM
Truist Securities analyst Robyn Karnauskas weighed in on the FDA briefing documents for Biogen's (NASDAQ: BIIB) aducanumab, saying the FDA ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Trader Talk
Next Articles
AC Immune SA (ACIU) Gains on Biogen Briefing Documents
November 4, 2020 10:21 AM
Biogen (BIIB) Halted on LUDP
November 4, 2020 10:12 AM
Biogen (BIIB) Spikes 14% After FDA Posts Briefing Documents for Alzheimer's Drug Aducanumab
November 4, 2020 10:11 AM
Tech, health stocks rise, cyclicals fall on prospects of divided U.S. Congress
November 4, 2020 7:00 AM